Table 2.
Subgroup analysis of the prevalence (p) of HIV treatment failure based on overall HAART, immunological, virological, and clinical definition by region, age, and study design in Ethiopia
| Subgroup analysis | Overall HAART failure P (95%CI) | Immunological failure P (95%CI) | Virological failure P (95%CI) | Clinical failure P (95% CI) |
|---|---|---|---|---|
| By Region | ||||
| Amhara | 13.7 (7.3–20.2) | 9.3 (3.3–15.2) | 7.1 (0.03–14.1) | 5.7 (2.6–8.9) |
| Oromia | 18.8 (16.8–20.8) | 8.9 (4.2–13.6) | 5.3 (3.8–6.8) | 8.8 (1.9–15.7) |
| Addis Ababa | 18.4 (13.6–23.3) | 13.2 (7.9–18.4) | 1.5 (1.0–2.0) | 5.5 (4.4–6.6) |
| Tigray | __ | 6.5 (4.9–8.2) | 11.5 (9.6–13.4) | __ |
| By age of participants | ||||
| All age group | 20.0 (18.4–21.6) | 11.2 (2.0–20.4) | 11.0 (9.9–12.2) | 11.2 (9.7–12.7) |
| Adult | 16.0 (7.4–24.7) | 12.9 (7.6–18.3) | 2.8 (1.5–4.1) | 4.6 (2.9–6.3) |
| Children | 14.6 (9.7–19.6) | 6.4 (3.6–9.3) | __ | 6.4 (4.2–8.5) |
| By Study design | ||||
| Cross-sectional | 14.1 (3.0–25.2) | 8.1 (2.7–13.5) | 8.5 (3.2–13.9) | 7.2 (0.8–15.8) |
| Cohort | 16.8 (12.2–21.37) | 11.2 (6.8–15.6) | 2.6 (1.1–4.0) | 6.0 (4.5–7.5) |
| Combined | 15.8 (11.6–20.1) | 10.2 (6.9–13.6) | 5.6 (2.9–8.3) | 6.3 (4.6–8.0) |
__ denotes no estimation due to lack of original studies